Skin sensitivity to topical products does not predict reaction severity to subcutaneous injections
Setting Realistic Expectations Understanding the typical semaglutide timeline helps prevent discouragement during the early weeks when dose adjustments may cause temporary side effects and weight loss is just beginning
Nausea is reported in approximately 1530% of patients in clinical trials and is the most common reason for treatment discontinuation
Compared to the use of GLP1-RAs alone, the combination of SGLT2is and GLP1-RAs was associated with a 30% reduction in the risk of MACE, with rates of 7.0 versus 10.3 events per 1000 person-years (HR 0.70
But over time, improper storage can affect results
Patients should contact their GP or bariatric team if they experience persistent vomiting, signs of dehydration, severe abdominal pain, visual changes, jaundice, or symptoms of hypoglycaemia